CTACK/CCL27 expression in psoriatic skin and its modification after administration of etanercept

British Journal of Dermatology

Volumn 157, Issue 6, 2007, Pages 1155-1160

  Campanati, A ^a   Goteri, G ^a   Simonetti, O ^a   Ganzetti, G ^a   Giuliodori, K ^a   Stramazzotti, D ^a   Morichetti, D ^a   Bernardini, M L ^a   Mannello, B ^a   Fabris, G ^a   Offidani, A ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

CCL27; CTACK; Etanercept; Psoriasis

Indexed keywords

CHEMOKINE; CUTANEOUS T CELL ATTRACTING CHEMOKINE; ETANERCEPT; UNCLASSIFIED DRUG;

ARTICLE; CELL MIGRATION; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DRUG DOSE COMPARISON; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PSORIASIS; SKIN CULTURE; SKIN DISEASE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMOKINE CCL27; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; MALE; PSORIASIS; RECEPTORS, CHEMOKINE; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 36148986520     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.08200.x     Document Type: Article

References (17)

1. Lowes MA, Chamian F, Abello MV et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 2005 102 : 19057 62.
2. Giustizieri ML, Mascia F, Frezzolini A et al. Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol 2001 107 : 871 7.
3. Kakinuma T, Saeki H, Tsunemi Y et al. Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris. J Allergy Clin Immunol 2003 111 : 592 7.
4. Banno T, Gazel A, Blumenberg M. Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling. J Biol Chem 2004 279 : 32633 42.
5. Vestergaard C, Johansen C, Otkjaer K et al. Tumor necrosis factor-alpha induced CTACK/CCL27 (cutaneous T-cell-attracting chemokine) production in keratinocytes is controlled by nuclear factor κB. Cytokine 2005 29 : 49 55.
6. Morales J, Homey B, Vicari AP et al. CTACK, a skin-associated chemokine that preferentially attracts skinhoming memory T cells. Proc Natl Acad Sci USA 1999 96 : 14470 5.
7. Ishikawa-Mochizuki I, Kitaura M, Baba M et al. Molecular cloning of a novel CC chemokine, interleukin-11 receptor a-locus chemokine (ILC), which is located on chromosome 9p13 and a potential homologue of a CC chemokine encoded by molluscum contagiosum virus. FEBS Lett 1999 460 : 544 8.
8. Kunkel EJ, Butcher EC. Chemokines and the tissue-specific migration of lymphocytes. Immunity 2002 16 : 1 4.
9. Reiss Y, Proudfoot AE, Power CA et al. CC chemokine receptor (CCR) 4 and the CCR10 ligand cutaneous T cell attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med 2001 194 : 1541 7.
10. Homey B, Alenius H, Muller A et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med 2002 8 : 157 65.
11. Weinberg JM. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther 2003 25 : 2487 505.
12. Krueger GG, Langley RG, Finlay AY et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 2005 153 : 1192 9.
13. Papp KA, Tyring S, Lahfa M et al. Etanercept Psoriasis Study Group. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005 152 : 1304 12.
14. Feldman SR, Kimball AB, Krueger GG et al. Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol 2005 53 : 887 9.
15. Gottlieb AB, Leonardi CL, Goffe BS et al. Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. J Am Acad Dermatol 2006 54 : S92 100.
16. Gordon K, Korman N, Frankel E et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol 2006 54 : S101 11.
17. Homey B, Wang W, Soto H et al. The orphan chemokine receptor G protein-coupled receptor-2 (GPR-2, CCR10) binds the skin associated chemokine CCL27 (CTACK/ALP/ILC). J Immunol 2000 164 : 3465 70.